AI Summary
5 min read🎙️ The Voices & The Context
- The Format: This episode serves as a casual chat between hosts Tracy Alloway and Joe Weisenthal, punctuated by an insightful guest interview that explores the intersections of music, investing, and healthcare.
- The Key Players:
- Tracy Alloway: Co-host, known for her analytical approach to finance and economics.
- Joe Weisenthal: Co-host, recognized for his lively and inquisitive nature.
- DA Wallach: Guest, a biotech investor and former lead singer of Chester French, bringing a unique perspective from both the music and investment worlds.
🗝️ Key Themes & Topics
- Healthcare System Complexity: Tracy and Joe highlight their intimidation by the US healthcare system and express a desire to explore this topic more deeply, emphasizing the need for understanding the intertwining of healthcare and finance.
- Biotech Investment Landscape: DA shares his journey from music to biotech investing and discusses the nuances of evaluating biotech companies, including the challenges posed by low success rates in drug development.
- AI in Healthcare and Music: The episode touches on the impact of AI in both the healthcare sector and the music industry, with DA sharing his thoughts on how AI can facilitate advancements while acknowledging the unique creative challenges it presents.
- **Cultural Perspectives on Medic
Continue reading the full summary in the app — free to try.
Read Full Summary →Free • No credit card required
What you'll learn
- 1 `(00:00)` **🎙️ Introduction: DA Wallach**
- 2 `(03:40)` **Healthcare Episode Context**
- 3 `(05:54)` **DA Wallach's Background**
- 4 `(08:19)` **The Connection Between Music and Biotech**
- 5 `(09:47)` **Investing in Biotech**
- 6 `(11:33)` **Sourcing Biotech Investments**
- 7 `(13:47)` **The Valley of Death in Biotech**
+ Full timestamped outline available in the app
Show Notes
Most people think of venture capital as funding software startups or, these days, some new AI tool. But VC also plays a major role in developing new medicines and treatments. That’s the world of D.A. Wallach — though he didn’t start there. Before becoming a biotech investor, Wallach was the lead singer of the indie rock band Chester French. So how did he make the leap from music to venture capital? How does he spot promising biotech opportunities? What does it actually take to bring a new drug to market? And how does biotech investing differ from traditional VC? We talk to the co-founder of Time BioVentures about all of this — plus we get his thoughts on AI’s impact on music and a special performance.
Have a question for Joe and Tracy? Now's your chance to be the perfect guest - record a voice memo with your name, age, location and question and email to [email protected] for a chance to be included in the holiday AMA episode.
Read More:
Big Pharma’s Patent Cliff Puts China Front and Center
Novartis Strikes Deal With UK Biotech for Up To $1.7 Billion
Join the conversation: discord.gg/oddlots
Only Bloomberg.com subscribers can get the Odd Lots newsletter in their inbox — now delivered every weekday — plus unlimited access to the site and app. bloomberg.com/subscriptions/oddlots
See omnystudio.com/listener for privacy information.
More from this podcast
Odd Lots →